bioRxivMicrobiology
Inactivation of SARS-CoV-2 by β-propiolactone Causes Aggregation of Viral Particles and Loss of Antigenic Potential
D. Gupta, H. Parthasarathy, V. Sah, D. Tandel, D. Vedagiri, S. Reddy, K. H. Harshan
Abstract
Inactivated viral preparations are important resources in vaccine and antisera industry. Of the many vaccines that are being developed against COVID-19, inactivated whole-virus vaccines are also considered effective. {beta}-propiolactone (BPL) is a widely used chemical inactivator of several viruses. Here, we analyze various concentrations of BPL to effectively inactivate SARS-CoV-2 and their effects on the biochemical properties of the virion particles. BPL at 1:2000 (v/v) concentrations effectively inactivated SARS-CoV-2. However, higher BPL concentrations resulted in the loss of both protein content as well as the antigenic integrity of the structural proteins. Higher concentrations also caused substantial aggregation of the virion particles possibly causing undesirable outcomes including a potential immune escape by infectious virions, and a loss in antigenic potential. We also identify that the viral RNA content in the culture supernatants can be a direct indicator of their antigenic content. Our findings may have important implications in the vaccine and antisera industry during COVID-19 pandemic.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Effects of inactivation method on SARS-CoV-2 virion proteins and structure
E. K. Loveday, K. S. Hain, … M. P. Taylor·bioRxiv·Nov 14, 2020
- Assessment of Inactivation Procedures for SARS-CoV-2
H. Auerswald, S. Yann, … J. A. Garcia-Rivera·bioRxiv·May 28, 2020
- Methods of inactivation of SARS-CoV-2 for downstream biological assays
E. I. Patterson, T. Prince, … G. L. Hughes·bioRxiv·May 21, 2020
- Inactivation of SARS Coronavirus 2 and COVID-19 patient samples for contemporary immunology and metabolomics studies
D. J. Eddins, L. C. Bassit, … E. Ghosn·bioRxiv·Oct 22, 2021
- Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings
S. Westhaus, M. Widera, … S. Ciesek·bioRxiv·Sep 11, 2020
- Preliminary stability studies of a ss-SARS-CoV-2 virus-like particle vaccine
Melissa Anne Edeling, Linda Earnest, … Joseph Torresi·bioRxiv·Mar 12, 2026